Diffuse Intrinsic Pontine Glioma Clinical Trials

22 recruiting

Diffuse Intrinsic Pontine Glioma Trials at a Glance

27 actively recruiting trials for diffuse intrinsic pontine glioma are listed on ClinicalTrialsFinder across 6 cities in 16 countries. The largest study group is Phase 1 with 15 trials, with the heaviest enrollment activity in Seattle, Cincinnati, and Washington D.C.. Lead sponsors running diffuse intrinsic pontine glioma studies include Nationwide Children's Hospital, Children's Oncology Group, and Capital Medical University.

Browse diffuse intrinsic pontine glioma trials by phase

Treatments under study

About Diffuse Intrinsic Pontine Glioma Clinical Trials

Looking for clinical trials for Diffuse Intrinsic Pontine Glioma? There are currently 22 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Diffuse Intrinsic Pontine Glioma trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Diffuse Intrinsic Pontine Glioma clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 27 trials

Recruiting
Phase 1

C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

High Grade GliomaDiffuse Intrinsic Pontine GliomaEmbryonal Tumor+1 more
Baylor College of Medicine56 enrolled1 locationNCT04099797
Recruiting
Phase 2

Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+7 more
Nationwide Children's Hospital120 enrolled21 locationsNCT05843253
Recruiting
Phase 1Phase 2

Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors

MeningiomaRecurrent Diffuse Intrinsic Pontine GliomaHigh Grade Glioma+10 more
Nationwide Children's Hospital65 enrolled4 locationsNCT05278208
Recruiting
Phase 1Phase 2

Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas

OsteosarcomaEwing SarcomaNeuroblastoma+4 more
Milton S. Hershey Medical Center289 enrolled10 locationsNCT06465199
Recruiting
Phase 1

Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors

Germ Cell TumorChoroid Plexus CarcinomaCentral Nervous System Tumor+8 more
Seattle Children's Hospital90 enrolled1 locationNCT04185038
Recruiting
Phase 2

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

High Grade GliomaDiffuse Intrinsic Pontine GliomaRecurrent Medulloblastoma
Nationwide Children's Hospital120 enrolled12 locationsNCT05096481
Recruiting

Targeted Pediatric High-Grade Glioma Therapy

Metastatic Brain TumorGlioblastomaGlioblastoma Multiforme+6 more
Nationwide Children's Hospital350 enrolled21 locationsNCT05839379
Recruiting
Phase 2

ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas

Diffuse Intrinsic Pontine Gliomas (DIPG)Progressive DIPGRefractory DIPG+2 more
Nationwide Children's Hospital60 enrolled20 locationsNCT06838676
Recruiting
Phase 1Phase 2

H3K27M-specific Immune Effector Cells Targeting DMG/DIPG

Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma
Shenzhen Geno-Immune Medical Institute30 enrolled1 locationNCT07501156
Recruiting
Early Phase 1

A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion

High Grade GliomaDiffuse Intrinsic Pontine Glioma
Nationwide Children's Hospital15 enrolled21 locationsNCT04655404
Recruiting
Phase 1

rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG

Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-Mutant
Ann & Robert H Lurie Children's Hospital of Chicago36 enrolled3 locationsNCT04943848
Recruiting
Early Phase 1

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

GlioblastomaGlioblastoma MultiformeHigh Grade Glioma+6 more
Nationwide Children's Hospital15 enrolled18 locationsNCT06333899
Recruiting
Phase 1

Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma

Childhood AstrocytomaChildhood Diffuse Intrinsic Pontine GliomaChildhood Diffuse Midline Glioma+2 more
Children's Oncology Group54 enrolled17 locationsNCT06894979
Recruiting
Phase 1Phase 2

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Recurrent Malignant Solid NeoplasmRefractory Malignant Solid NeoplasmRecurrent Lymphoma+7 more
Children's Oncology Group63 enrolled34 locationsNCT04870944
Recruiting
Phase 3

Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0

Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3K27-alteredDiffuse Midline Glioma, H3 K27M-Mutant
Gustave Roussy, Cancer Campus, Grand Paris433 enrolled50 locationsNCT05476939
Recruiting
Phase 1

FUS Etoposide for DMG

Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-Mutant
Columbia University10 enrolled1 locationNCT05762419
Recruiting
Phase 2

Combination Therapy for the Treatment of Diffuse Midline Gliomas

Recurrent Diffuse Intrinsic Pontine GliomaDiffuse Intrinsic Pontine GliomaWHO Grade III Glioma+3 more
University of California, San Francisco360 enrolled32 locationsNCT05009992
Recruiting
Phase 1Phase 2

Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age

Glioblastoma MultiformeOligodendrogliomaDiffuse Intrinsic Pontine Glioma+5 more
University of Miami20 enrolled1 locationNCT05956821
Recruiting

International Diffuse Intrinsic Pontine Glioma (DIPG)/Diffuse Midline Glioma (DMG) Registry and Repository

Diffuse Intrinsic Pontine GliomaDiffuse Midline Glioma, H3 K27M-MutantDiffuse Midline Glioma
Children's Hospital Medical Center, Cincinnati1,500 enrolled1 locationNCT03101813
Recruiting
Phase 1

Safety and Efficacy of Loco-regional B7H3 IL-7Ra CAR T Cell in DIPG

Diffuse Intrinsic Pontine GliomaDIPG Brain Tumor
Chulalongkorn University9 enrolled1 locationNCT06221553